Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”. Determining which patients will benefit remains an important clinical goal. In a non-inflamed tumor mouse model, we found that PD-L1 was highly expressed on antigen-presenting cells (APCs) especially on CD103(+...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Iwai, Toshiki, Sugimoto, Masamichi, Patil, Namrata S., Bower, Daniel, Suzuki, Miho, Kato, Chie, Yorozu, Keigo, Kurasawa, Mitsue, Shames, David S., Kondoh, Osamu
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8260627/
https://ncbi.nlm.nih.gov/pubmed/34230534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-93113-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky